{
  "id": "6020b0e21cb411341a000085",
  "type": "yesno",
  "question": "Is Eflornithine and Sulindac are effective for prevention of progression in Familial Adenomatous Polyposis?",
  "ideal_answer": "No. In a clinical trial, the incidence of progression in Familial Adenomatous Polyposis was not significantly lower with the combination of eflornithine and sulindac than with either drug alone.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32905675"
  ],
  "snippets": [
    {
      "text": "Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905675",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: The efficacy and safety of combination therapy with eflornithine and sulindac, as compared with either drug alone, in delaying disease progression in patients with familial adenomatous polyposis are unknown.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905675",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this trial involving patients with familial adenomatous polyposis, the incidence of disease progression was not significantly lower with the combination of eflornithine and sulindac than with either drug alone. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905675",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Disease progression occurred in 18 of 56 patients (32%) in the eflornithine-sulindac group, 22 of 58 (38%) in the sulindac group, and 23 of 57 (40%) in the eflornithine group, with a hazard ratio of 0.71 (95% confidence interval [CI], 0.39 to 1.32) for eflornithine-sulindac as compared with sulindac (P\u2009=\u20090.29) and 0.66 (95% CI, 0.36 to 1.24) for eflornithine-sulindac as compared with eflornithine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905675",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: In this trial involving patients with familial adenomatous polyposis, the incidence of disease progression was not significantly lower with the combination of eflornithine and sulindac than with either drug alone. (Fund",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905675",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The efficacy and safety of combination therapy with eflornithine and sulindac, as compared with either drug alone, in delaying disease progression in patients with familial adenomatous polyposis a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905675",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "this trial involving patients with familial adenomatous polyposis, the incidence of disease progression was not significantly lower with the combination of eflornithine and sulindac than with either drug alone. (F",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32905675",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}